Surveillance for 3.7 cm Thyroid Nodule Bethesda Category II
For a 3.7 cm Bethesda II thyroid nodule, perform ultrasound surveillance at 1-2 years after initial diagnosis, then every 2-4 years thereafter, with closer monitoring (every 1-2 years) if the nodule is EU-TIRADS 5 or if this is a recently discovered large nodule requiring assessment of growth trajectory. 1
Key Surveillance Strategy
The 2022 SFE-AFCE-SFMN consensus guidelines provide clear direction for your specific scenario:
Standard Surveillance Protocol
- First follow-up: 1-2 years after initial diagnosis
- Subsequent follow-ups: Every 2-4 years if stable
- No routine repeat FNAB unless specific concerning features develop 1
Critical Modifier: Size >4 cm Consideration
Your 3.7 cm nodule falls just below the 4 cm threshold that triggers special consideration. The guidelines specifically note that asymptomatic nodules >4 cm that are recently discovered warrant closer surveillance to determine growth trajectory and guide potential therapeutic intervention (surgery or thermal ablation) 1. While your nodule is 3.7 cm, this principle suggests maintaining vigilance for growth patterns.
EU-TIRADS Score Determines Intensity
The surveillance interval critically depends on the ultrasound risk stratification:
If EU-TIRADS 2,3, or 4:
- Follow the standard 1-2 year initial follow-up, then 2-4 years 1
- Malignancy risk is only 0.6% for non-suspicious nodules with benign cytology 1
- Research confirms 3.2% overall malignancy rate in Bethesda II nodules, supporting conservative surveillance 2
If EU-TIRADS 5:
- More intensive surveillance: Every 1-2 years for 5 years, then space out if stable 1
- Malignancy risk increases to 3-8.6% despite benign cytology 1
- This represents ultrasound-cytology discrepancy requiring heightened vigilance
When to Repeat FNAB
Do NOT routinely repeat FNAB for Bethesda II nodules unless specific criteria develop 1:
Indications for repeat FNAB:
- Significant growth: ≥20% increase in two of three dimensions (though interpret cautiously based on initial size and solid vs. cystic composition) 1
- New suspicious ultrasound features emerge
- EU-TIRADS 5 with multiple high-risk features: marked hypoechogenicity, taller-than-wide, microcalcifications, irregular margins 1
Why repeat FNAB is generally unnecessary:
- Only 1-2.6% malignancy rate in Bethesda II nodules followed with surveillance or repeat FNAB 1
- Most nodules remain stable; new cancer detection is rare 1
- Recent data shows 40.4% of Bethesda II nodules upgraded on repeat FNA, but this should be triggered by clinical/sonographic changes, not routine protocol 3
Growth Patterns to Monitor
Over 5 years of surveillance 1:
- 11-29% of nodules show growth (mean increase 5.9 mm)
- 13-18% spontaneously decrease
- Risk factors for growth: male gender, age <45 years, volume >0.2 cm³ (>7.5 mm)
For your 3.7 cm nodule, document baseline measurements carefully to assess any meaningful change at follow-up.
Clinical Pitfalls to Avoid
Don't over-surveil: Ultrasound should not be repeated too frequently given the low malignancy risk 1
Size alone doesn't mandate repeat FNAB: Historical data suggesting higher cancer rates in large benign nodules used surgical series (selection bias). Studies using cytology/surveillance as gold standard show <1.5% cancer rates 1
Interpret "growth" contextually: A 20% increase in an 8 mm nodule differs from 20% in a 4 cm nodule; consider solid vs. cystic composition and inter-operator variability 1
Consider discontinuation in elderly patients: If the nodule remains stable and non-suspicious, monitoring may be discontinued in older patients with non-suspicious disease 1
Special Consideration for Your Case
Given your nodule is 3.7 cm and recently discovered (implied by seeking surveillance guidance), consider:
- Initial closer surveillance (toward the 1-year mark) to establish growth trajectory
- If stable at first follow-up, extend to 2-4 year intervals
- Assess for any compressive symptoms or cosmetic concerns that might favor intervention regardless of cytology